Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Beroterkib

Generic Name: Beroterkib

Overview

No overview information available.

Background

No background information available.

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Clinical Trials

Phase I/II Study of a Combination of Decitabine and Cedazuridine (ASTX727) and ASTX029, an ERK Inhibitor, for Patients With RAS Pathway Mutant Myelodysplastic Syndromes and Myelodysplastic/Myeloproliferative Neoplasms

Phase 1

Withdrawn

Posted: 2024/02/29

Sponsor:M.D. Anderson Cancer...

ID:NCT06284460

A Phase 1 Study to Evaluate the Effect of Food on Pharmacokinetics of ASTX029

Phase 1

Completed

Posted: 2020/07/10

Sponsor:Astex Pharmaceutical...

ID:NCT04466514

Study of ASTX029 in Subjects With Advanced Solid Tumors

Phase 1

Active, not recruiting

Posted: 2018/05/09

Sponsor:Taiho Oncology, Inc.

ID:NCT03520075

FDA Approved Products

No FDA products found for this drug

Singapore Approved Products

No Singapore products found for this drug

Related News

Mosaic Therapeutics Acquires Two Clinical-Stage Oncology Programs from Astex to Develop Novel Combination Therapies

a month ago

Mosaic Therapeutics has in-licensed two clinical-stage oncology programs from Astex Pharmaceuticals, including an ERK1/2 inhibitor and an MDM2 antagonist, both showing promising safety profiles in over 100 patients.

Drug Development Updates

Stay informed with timely notifications on clinical trials and research advancements.

Home Terms & Conditions Privacy Policy